Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | ||||||
{[ item.p_purity ]} | {[ item.pr_size ]} | Inquiry |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price) ]} |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price) ]} | {[ item.pr_usastock ]} | in stock Inquiry - | {[ item.pr_chinastock ]} | {[ item.pr_remark ]} in stock Inquiry - | Login | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
Flavio S.P. Cardoso ; Appasaheb L. Kadam ; Ryan C. Nelson , et al. Org. Process Res. Dev.,2023,27(7):1390-1399. DOI: 10.1021/acs.oprd.3c00148 PubMed ID: 37496954
More
Abstract: A low-cost, protecting group-free route to 6-(2-fluoro-4-nitrophenyl)-2-oxa-6-azaspiro[3.3]heptane (1), the starting material for the in-development tuberculosis treatment TBI-223, is described. The key bond forming step in this route is the creation of the azetidine ring through a hydroxide-facilitated alkylation of 2-fluoro-4-nitroaniline (2) with 3,3-bis(bromomethyl)oxetane (BBMO, 3). After optimization, this ring formation reaction was demonstrated at 100 g scale with isolated yield of 87% and final product purity of >99%. The alkylating agent 3 was synthesized using an optimized procedure that starts from tribromoneopentyl alcohol (TBNPA, 4), a commercially available flame retardant. Treatment of 4 with sodium hydroxide under Schotten–Baumann conditions closed the oxetane ring, and after distillation, 3 was recovered in 72% yield and >95% purity. This new approach to compound 1 avoids the previous drawbacks associated with the synthesis of 2-oxa-6-azaspiro[3,3]heptane (5), the major cost driver used in previous routes to TBI-223. The optimization and multigram scale-up results for this new route are reported herein.
Keywords: tuberculosis ; TBI-223 ; azaspiro[3.3]heptane ; spiroamine
Purchased from AmBeed: 2402-83-7 ; 369-35-7 ; 1522-92-5 ; 1975218-55-3
CAS No. : | 1522-92-5 | MDL No. : | MFCD00021982 |
Formula : | C5H9Br3O | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | QEJPOEGPNIVDMK-UHFFFAOYSA-N |
M.W : | 324.84 | Pubchem ID : | 15206 |
Synonyms : |
|
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P501-P261-P270-P271-P264-P280-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330-P302+P352+P312-P304+P340+P312 | UN#: | N/A |
Hazard Statements: | H302+H312+H332-H315-H319 | Packing Group: | N/A |
GHS Pictogram: |
![]() |
[ 41459-42-1 ]
3-Bromo-2-(bromomethyl)propanoic acid
Similarity: 0.63
[ 78385-26-9 ]
3-(Bromomethyl)-3-methyloxetane
Similarity: 0.75
[ 22633-44-9 ]
(3-(Bromomethyl)oxetan-3-yl)methanol
Similarity: 0.71
[ 22633-44-9 ]
(3-(Bromomethyl)oxetan-3-yl)methanol
Similarity: 0.71